Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05665387 · ClinicalTrials.gov registry record · Phase 2
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
A Phase 2 study, sponsored by Santen.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT05665387 is a Phase 2 study that has completed, run by Santen. The registered enrollment target is 79 participants.
The verdict
NCT05665387, a Phase 2 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
This is a Phase IIa study to assess efficacy and safety of STN1013600 ophthalmic solution (0.1%, and 0.3 %), twice daily when compared to Placebo in subjects diagnosed with presbyopia. This study will consist of a Screening Period of up to 15 days followed by a 2 Month Treatment Period. After the Treatment Period subjects will be followed for a one-month treatment free period.
Interventions
- DRUG Placebo
- DRUG 0.1% STN1013600 ophthalmic solution
- DRUG 0.3% STN1013600 ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05665387
The ClinicalTrials.gov registry entry for NCT05665387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05665387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05665387 about?
NCT05665387 is a clinical study titled "Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia". This is a Phase IIa study to assess efficacy and safety of STN1013600 ophthalmic solution (0.1%, and 0.3 %), twice daily when compared to Placebo in subjects diagnosed with presbyopia. This study will consist of a Screening Period of up to 15 days followed by a 2 Month Treatment Period. After the Tr...
What is the current status of trial NCT05665387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2022-12-22. Estimated completion is 2023-07-27.
What interventions are being tested in trial NCT05665387?
The interventions under investigation include: Placebo (DRUG), 0.1% STN1013600 ophthalmic solution (DRUG), 0.3% STN1013600 ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT05665387?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.